VANCOUVER, British Columbia, June 19, 2019 (GLOBE NEWSWIRE) -- NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has received an initial order from Cryopharm Corporation (“Cryopharm”).
NeutriSci licensed its Cryolization technology to Cryopharm for the manufacturing and distribution of buccal and sublingual rapid release consumable products utilizing both CBD and THC molecules. Cryopharm has placed its order for NeutriSci’s core ingredients, which form the basis of the company’s Marbl Melts. In addition to purchasing the core ingredients from NeutriSci, under the licensing terms, Cryopharm will pay NeutriSci a license fee, and a royalty on gross sales.
Cryopharm is a licensed THC manufacturer and distributor of medical grade, dose-controlled recreational and medicinal cannabis products with production facilities in Sacramento, California. Cryopharm and its American subsidiary are producing 12 different SKU’s and 3 brands which are to be distributed across California, with planned expansion into Nevada, Michigan, Illinois, Oregon, Colorado and Canada expected in 2019.
Cryopharm COO, Ryan Erving stated, “Cryopharm has been working with NeutriSci for almost a year, evaluating its stable of IP; both its own and some of which it had licensed from 3rd parties. After conducting an exhaustive number of trials, we are excited to be able to partner with NeutriSci, ultimately growing the Cryolization technology together. It is our belief this technology is a game changer in the consumable THC / CBD market space. We believe NeutriSci’s technology provides the ability to bring the highest efficacy and a fast-acting reaction time of any drug delivery system to bring the most efficient and effective consumables to the marketplace.”
NeutriSci CEO, Glen Rehman stated, “This has been a long process that has culminated with what I believe will be a very profitable partnership for NeutriSci for many years to come. We are very excited by the long-term potential of this agreement.”
NeutriSci expects to announce further distribution alliances and additional sales of its IP and product lines over the next few months.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
NeutriSci International Inc.
Tel: (403) 264-6320
Email: investors@neutrisci.com
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
For more information, please visit: www.neutrisci.com.
About Cryopharm Corporation
Cryopharm is a developer, producer and distributor of medical grade, dose-controlled recreational cannabis products. Marbl Melts are an industry-first rapidly dissolving cannabis melt product infused with THC and/or CBD. For more information, please visit: www.cryopharm.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.